{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:35:34Z","timestamp":1787758534011,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The study aimed to investigate the relationship between refractive outcomes with the extent of retinal vascularization and severity of the plus disease in infants treated with intravitreal bevacizumab (IVB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Pre-IVB fundus images (PFIs), final fundus images (FFIs), and refractive outcomes of the 93 infants who underwent IVB monotherapy for type 1 and aggressive retinopathy of prematurity (A-ROP) were retrospectively evaluated. Quantitative measurements were performed on PFIs and FFIs. Pre-IVB plus severity was scored on a five-leveled scale. Correlation between spherical equivalent (SE) with pre-treatment and final extent of the temporal retinal vascularization and pre-treatment severity of plus disease was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There was a linear and low positive correlation between the extent of pre-IVB and final temporal retinal vascularization with final SE (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.000, r = 0.267;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002, r = 0.274, respectively). There was a low negative correlation between the pre-IVB plus severity score with final SE (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.012, r = -0.192). Gestational age (GA), birth weight (BW), IVB dose, presence of additional IVB, or laser treatments were not correlated with refractive outcome. Out of 171 eyes, 38 eyes had &gt;1 D myopia. In the univariate logistic analyses, pre-IVB retinal zone and pre-IVB and final extent of the temporal retinal vascularization were found to be related to the development of &gt;1 D myopia (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.002, odds ratio (OR) = 0.298;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.000, OR = 0.281;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001, OR = 0.317; respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study indicates that the pre-treatment and final extent of retinal vascularization were the main parameters that were related to final refractive outcomes in IVB-treated eyes for type 1 and A-ROP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_243_22","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:10:13Z","timestamp":1665054613000},"page":"3584-3590","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab"],"prefix":"10.4103","volume":"70","author":[{"given":"Sadik Etka","family":"Bayramoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihat","family":"Sayin","sequence":"additional","affiliation":[{"name":"Department of Health Science University Kanuni Sultan Suleyman Training and Research Hospital, Tertiary ROP Center, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2017.04.010","article-title":"Anterior chamber angle and anterior segment structure of eyes in children with early stages of retinopathy of prematurity","volume":"179","author":"Chang","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/archopht.1990.01070120056029","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity:One-year outcome:Structure and function","volume":"108","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity:Results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment:A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B7-20240828","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner","year":"2008","journal-title":"Retina"},{"key":"B9-20240828","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-022-02321-6","article-title":"Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity:The importance of retinal vascularization","author":"Bayramoglu","year":"2022","journal-title":"Int Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ophtha.2018.12.034","article-title":"Describing retinopathy of prematurity:Current limitations and new challenges","volume":"126","author":"Fielder","year":"2019","journal-title":"Ophthalmology"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000521070","article-title":"The effect of intravitreal bevacizumab dose on retinal vascular progression in retinopathy of prematurity","volume":"245","author":"Bayramoglu","year":"2022","journal-title":"Ophthalmologica"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1177\/11206721211064019","article-title":"Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment","volume":"32","author":"Bayramoglu","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"B15-20240828","first-page":"1","article-title":"Fluorescein angiography findings in treatment-naive premature infants with retinal vascular immaturity and persistent avascular retina","author":"Bayramoglu","year":"2022","journal-title":"Semin Ophthalmol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1167\/iovs.12-9516","article-title":"Eye size in threshold retinopathy of prematurity, based on a Danish preterm infant series:Early axial eye growth, pre-and postnatal aspects","volume":"53","author":"Fledelius","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1167\/iovs.13-11765","article-title":"Development of refractive error in individual children with regressed retinopathy of prematurity","volume":"54","author":"Wang","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaapos.2007.08.012","article-title":"Long-term follow-up of visual functions in prematurely born children\u2014A prospective population-based study up to 10 years of age","volume":"12","author":"Holmstr\u00f6m","year":"2008","journal-title":"J AAPOS"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0161-6420(79)35437-9","article-title":"Anterior segment abnormalities in cicatricial retinopathy of prematurity","volume":"86","author":"Hittner","year":"1979","journal-title":"Ophthalmology"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ophtha.2012.02.040","article-title":"Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity","volume":"119","author":"Wu","year":"2012","journal-title":"Ophthalmology"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1167\/iovs.10-5234","article-title":"Long-term evaluation of refractive status and optical components in eyes of children born prematurely","volume":"51","author":"Chen","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1111\/aos.12053","article-title":"Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age","volume":"91","author":"Yang","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41433-019-0605-x","article-title":"Is the severity of refractive error dependent on the quantity and extent of retinal laser ablation for retinopathy of prematurity?","volume":"34","author":"Young-Zvandasara","year":"2020","journal-title":"Eye"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1038\/s41433-020-01321-z","article-title":"Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity","volume":"35","author":"Mori","year":"2021","journal-title":"Eye"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s10792-019-01088-7","article-title":"Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP","volume":"39","author":"Ekinci","year":"2019","journal-title":"Int Ophthalmol"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Gonzalez","year":"2018","journal-title":"Retina"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaapos.2018.10.013","article-title":"Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP","volume":"23","author":"Anand","year":"2019","journal-title":"J AAPOS"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_243_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:16:59Z","timestamp":1787757419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_243_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_243_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"2022-01-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}